Navigation Links
Congestive in Biological Technology

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the total ... should be carefully monitored congestive heart failure or cardiomyopathy may occur after ... events (including myocardial infarction, stroke, congestive heart failure, and hemodialysis vascular access ...

Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy

... intended to prevent or reverse the progression of congestive heart failure in patients who have an enlarged ... heart mitral valve which contributed to congestive heart failure. During the surgery to repair the ... of the left ventricle, which is typical in congestive heart failure. As such, this new therapy has the ...

KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure

... evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available ... "In 25 years of experience in treating congestive heart failure, we have consistently seen the best ... levels in these seven patients with end-stage congestive heart failure was associated with overall ...

Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients

... this tremendous opportunity to better serve the congestive Heart Failure patient population and their ... available through physician prescription. ABOUT congestive HEART FAILURE congestive heart failure (CHF), or heart failure, is a ...

Bioheart, Inc. Announces Financial Results for First Quarter 2008

... cardiac devices who are experiencing congestive heart failure. -- Bioheart initiated its ... expand our clinical body of evidence in treating congestive heart failure patients. This Phase II/III, ... myoblasts to treat patients suffering from congestive heart failure. These myoblasts, adult stem cells ...

Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results

... use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The ... the next fiscal year for treatment of acute congestive heart failure; -- Advancing new Palatin ... use in treatment of acute systemic hypertension, congestive heart failure and other diseases. Palatin's ...

Genomics Likely to Replace Traditional Drug Therapies in Treating CHF

... NEW YORK, April 17 /PRNewswire/ -- The market for congestive heart failure (CHF) drug treatments was estimated ... to a new report by Kalorama Information, congestive Heart Failure: Major World Markets, Volume I: ... adequate answer. Kalorama Information's report congestive Heart Failure: Major World Markets, Volume I: ...

Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure

... development for treatment of acute decompensated congestive heart failure (CHF). The Phase I trial was ... the subcutaneous route of administration. About congestive Heart Failure (CHF) Currently in the U.S., CHF ... over 1,100,000 hospitalizations for CHF in 2004. congestive heart failure has tremendous human and financial ...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

... I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, ... safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s). MyoCell SDF-1 ...

Symphony Medical Changes Name to CardioPolymers, Inc.

... biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle." ... clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

... of doxorubicin, a dose at which 5.6% of patients are expected to develop congestive heart failure (CHF). At cumulative doses of doxorubicin in excess of ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...

FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia

... brain damage and death. In the treatment of hyponatremia associated with congestive heart failure, Vaprisol is indicated only for those patients for whom ... in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in ...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

... (23%, 0%), superficial edema (17%, 41%), generalized edema (2%, 4%), congestive heart failure/cardiac dysfunction (2%, 0%), pericardial effusion (1%, ... gastrointestinal bleeding (4%), dyspnea (3%), sepsis (1%), diarrhea (2%), congestive heart failure (2%), and pericardial effusion (1%). Grade 3/4 elevations ...

Novel gene found for dilated cardiomyopathy

... women and is most common between the ages of 20 and 60 years, although it also occurs in fetuses, newborns and children. About one in three cases of congestive heart failure is due to DCM, which also occurs in children. Dr. Towbin and his colleagues screened 208 patients, mostly children and young adults, ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise ...

Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices)

... and Director of Cardiac and Vascular diseases at Regenocyte Therapeutic, a company successfully treating patients with heart disease such as congestive heart failure and lung disease such as pulmonary fibrosis, COPD, and pulmonary hypertension. Adult stem cells have undergone much more research ...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy. Worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cases of CHF in patients with known cardiovascular risk factors have been ...

Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research

... now, every week, improving dozens and dozens of lives all over the world. He emphasized that "Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular dystrophy, ataxia, autism, COPD, emphysema, Crohn's, and ...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

... remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling. About ...

Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer

... in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. " Phase III Study Design The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who ...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

... in patients with HER-2 overexpressing breast cancer. The 3-drug combination was well tolerated. There were no cases of treatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer ...

Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study

... observed to have side effects of weight gain and abdominal obesity, which exacerbate the diabetic condition itself, and to cause edema and exacerbate congestive heart failure in certain patients. Individuals vary in their risk and there is no known method for predicting such side effects. FDA-mandated "black ...

Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet

... of certain beta blockers for the treatment of asthma," commented Amie E. Franklin, PhD, of Inverseon. "A similar story played out 10 years ago in congestive heart failure where certain beta blocker drugs have become billion dollar products." "The Lancet Comment on Inverseon's human asthma study ...

Victhom announces the completion of the second phase of the apnea therapy development

... disorder that happens mostly during sleep. Apnea is a co-morbidity with other physiological issues such as high blood pressure, heart attack, congestive heart failure, cardiac arrhythmia, stroke or depression. The National Sleep Foundation estimates that more than 18 million American adults suffer ...

InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

... TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from ...

VivoMetrics to Present at the 2009 Biotech Showcase

... using LifeShirt at nearly 300 leading research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease and cystic fibrosis. For more information, visit www.lifeshirt.com . Forward-looking ...

You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decade's 'Real Nutritional Heroes'

... Fatigue Syndrome and fibromyalgia as well as a general malaise of exhaustion," said Teitelbaum. Corvalen(R) is also used by physicians to treat congestive heart failure and to prepare patients for off-pump bypass surgery(1). "Bioenergy D-Ribose(TM) also has sweeping applications for healthy ...

New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease

... in patients treated with CIMZIA(R). There is no evidence that CIMZIA(R) therapy has an effect on in vivo coagulation. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA (R) has not been formally studied in patients with CHF. ...

Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True

... and communications solutions for military and civilian medical use. Aiming to improve the odds for people medically at risk from dehydration or congestive heart failure, ORNL and NMT were actively engaged in improving and miniaturizing NMT's proprietary, patented ZOE(TM), an FDA-approved noninvasive ...

Neurocrine Biosciences Reports Third Quarter 2008 Results

... a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression. Urocortin 2 for congestive Heart Failure (CHF) Continues Preclinical Evaluation Initiation of longer term (up to 72 hours in duration) Phase II clinical trials of urocortin 2 ...

Osteoporosis Drugs Increase Risk for Heart Problems

... heart disease or hypertension," said Jennifer Miranda, MD, Jackson Memorial Hospital, Miami, FL. "If left untreated, it can lead to pulmonary edema, congestive heart failure, or the formation of a blood clot that can cause a brain embolism and stroke." In a metaanalysis, Dr. Miranda and colleagues from the ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... seven deaths indicated above. - A third patient who was on pegloticase every 4 weeks, following a placebo dose had an SAE relating to congestive heart failure which was resolved after hospitalization. However, as previously reported, this patient died of renal failure after ...

BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza

... test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. Of the 137 patients ...

Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum

... Gerson Lehrman Group's leading physician consultants along with executives from public and private equity biotechnology companies to discuss: -- congestive Heart Failure -- Cystic Fibrosis -- Epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... consider the use of ERBITUX in combination with radiation therapy in head and neck cancer patients with a history of coronary artery disease, congestive heart failure or arrhythmias in light of these risks - Closely monitor serum electrolytes including serum magnesium, potassium, and calcium during ...

Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial

... complications such as pneumonia. In addition, influenza exacerbates the symptoms of chronic health conditions such as diabetes, asthma and congestive heart failure. The most severe disease occurs in infants and young children and adults older than 65 years of age. The CDC reports that 15 to 60 ...
Other Contents
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
(Date:8/28/2015)... ... August 28, 2015 , ... ... and Best Practices for Compliance, **Presented by FDAnews and GessNet**, Oct. 14-15, ... internationally renowned expert Fubin Wu, has been specifically designed to provide devicemakers ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best ... sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held in ... to raise money to support music education programs in the underfunded local school districts ...
(Date:8/28/2015)... ... 2015 , ... “ Frequentz ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... businesses to track product movement from beginning to end. , Businesses benefit greatly from ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest travel ... in Healthcare by Modern Healthcare and will be honored at an awards dinner ... year, the Best Places to Work in Healthcare program recognizes outstanding employers in the ...
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
Other TagsOther Tags